XM does not provide services to residents of the United States of America.

Rentokil hit by N.America woes; no immediate re-listing plans



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 2-Rentokil hit by N.America woes; no immediate re-listing plans</title></head><body>

2024 N.America organic revenue growth seen at lower end of range

No immediate plans to move listing to US

Shares fell as much as 7%

Rewrites, adds share milestones

By Yamini Kalia

July 25 (Reuters) -British pest control company Rentokil Initial RTO.L said on Thursday it expected underlying revenue at its North American business - the group's largest - to come in at the lower end of its forecast, sending its shares as much as 7% lower.

The company, which made about 60% of its revenue in North America last year, also said it had no immediate plans to move its listing to the United States, as some analysts had speculated.

"Going forward, the board will continue to keep the Group's listing structure under review to ensure that the strength of the Group's underlying financial performance and its prospects are appropriately valued," it said in a statement.

Rentokil's shares have fallen about 20% since it flagged softer demand in North America last October.

Earlier this month, the shares rose on reports ex-BT chief Philip Jansen was looking to buy the firm. They also jumped in June on news that activist investor Nelson Peltz's Trian Fund Management had built a stake in the company and was interested in discussing "ideas and initiatives".

In March, Rentokil said it expected organic revenue in North America to rise by 2-4% this year. On Thursday, it said it now expected revenue growth there at the lower end of this range.

For the second quarter, the key North American pest control business posted a 0.5% rise in organic revenue, compared with the previous quarter.

"Investors are ostensibly reacting to the muted quarter-on-quarter improvement in organic growth for the beleaguered North America pest control business," said Morningstar analyst Grant Slade.

Rentokil and rival Rollins ROL.N account for roughly half of the U.S. pest control market, with Rentokil the larger player after it bought U.S. rival Terminix.

Rollins posted a 7.7% organic revenue growth in the second quarter.

"Relative to the growth of the broader market, Rentokil is underperforming the peers while Rollins continues to outperform," Slade added.



Reporting by Yamini Kalia in Bengaluru; Editing by Sherry Jacob-Phillips and Mark Potter

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.